Details of the Drug Reposition

General Information of This Drug (ID: DM1WNGJ)

Drug Name
DFP-10917   DM1WNGJ
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
1 Phase 3 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Acute myeloid leukaemia DIS0BM1I 2A60 Phase 3 [1]
------------------------------------------------------------------------------------
1 Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Solid tumour/cancer DISZR48F 2A00-2F9Z Phase 2 [2]
------------------------------------------------------------------------------------
1 Phase 1/2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Acute lymphoblastic leukaemia DIS87TGM 2A85 Phase 1/2 [3]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT03926624) Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage. U.S. National Institutes of Health.
2 ClinicalTrials.gov (NCT00824161) Phase II Study of TAS-109 to Treat Advanced Colorectal Cancer. U.S. National Institutes of Health.
3 ClinicalTrials.gov (NCT01702155) Phase I/II Study of DFP-10917 in Patients With Acute Leukemia. U.S. National Institutes of Health.